James Halstead

James Halstead

Partner

jhalstead@cov.com
Download V-card

Covington & Burling LLP
265 Strand
London WC2R 1BH
Tel: +44 20 7067 2052

   

Education

  • College of Law, Chester, L.P.C., 1998
  • College of Law, Chester, C.P.E., 1997
  • University of Cambridge, B.A., 1996

Bar Admissions

  • Solicitor of the Senior Courts of England and Wales

James Halstead is a partner in the Corporate Practice and is resident in Covington's London office.

Mr. Halstead advises on a range of corporate transactions including mergers and acquisitions, initial public offerings, public and private financings, and restructurings.  Mr. Halstead also advises on commercial transactions including technology transfers, intellectual property pipeline arrangements, licensing and joint ventures.

Mr. Halstead acts for companies at all stages of development, as well as investors and management teams.  His practice covers a wide range of industries; he has particular expertise in advising on deals in the life sciences and technology sectors.  Chambers UK (2012) characterises him as "part of the next generation of top operators within the [life sciences] market.”

Representative Matters

  • Advised the management team on The Foundry’s investment from HgCapital under ther terms of which HgCapital assumed majority ownership from The Carlyle Group for an enterprise value of £200 million ($312 million USD). The Foundry is a leading provider of award-winning creative software.  
  • Advised Johnson & Johnson on the acquisition of XO1 Limited, an asset-centric biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab.
  • Advised Johnson & Johnson on the sale of its vaccine manufacturing business in Solna, Sweden to Valneva, a French pharmaceutical company listed on Euronext, Paris.
  • Advised OCP S.A. a leading producer of phosphate rock and phosphoric acid, on its acquisition of approximately 10% of the share capital of, and on its entry into a long-term supply agreement with, Brazilian listed fertilizer company, Fertilizantes Heringer S.A.
  • Advised Spanish pharmaceutical company, Laboratorios Esteve, S.A. in a global multi-programme discovery and development collaboration, with payments potentially exceeding $1 billion, with Mundipharma Laboratories GmbH and its independent associated company, Purdue Pharmaceuticals LP, to bring to market important next generation products for the management of pain.
  • Advised hit musical producer, Cameron Mackintosh Limited, on its acquisition of the Victoria Palace Theatre, London.
  • Advised AstraZeneca and MedImmune, its global biologics research and development arm, on the acquisition of Spirogen, a privately-held biotech company focused on antibody-drug conjugate technology for use in oncology.

Honors and Rankings

  • LMG Life Sciences Europe, Life Sciences Star - Financial & Transactional (United Kingdom) (2014)
  • Super Lawyers - London, Corporate Finance (2013)
  • Chambers UK, Life Sciences: Transactional (2011-2012)
  • Legal 500 UK, M&A - Upper Mid-Market & Premium Deals (2013)
  • Legal 500 UK, Equity Capital Markets (2012)
  • Legal 500 UK, Venture Capital (2012)
  • Legal 500 UK, Flotations, Small and Mid-Cap (2011-2012)
  • Legal 500 UK, Pharmaceuticals and Biotechnology (2011)

Publications and Speeches

  • "Starting the Commercialisation Process – What Issues do you need to Address," NanoEntrepreneurs Workshop "What does it take to commercialise micro & nanoscale research & development? (1/28/2014)
  • "Key Considerations for European M&A in the Life Sciences Sector," PLC Life Sciences Handbook 2012 (2012), Co-Author
  • "Financing UK Life Sciences," PLC Life Sciences Handbook (2010), Co-Author
Print PDF Word Version Print this page